Lutetium-177 Industry Research Report 2024: Carrier Added Lutetium-177, Non-Carrier-Added Lutetium-177 - Global Forecast 2024-2030
09 sept. 2024 04h56 HE
|
Research and Markets
Dublin, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The "Lutetium-177 Market by Form (Carrier Added Lutetium-177, Non-Carrier-Added Lutetium-177), Route of Administration (Intravenous, Oral), End User,...
Lutathera and Pepaxto Dominated the Peptide Drug Conjugates Market in 2022
18 oct. 2023 10h03 HE
|
Research and Markets
Dublin, Oct. 18, 2023 (GLOBE NEWSWIRE) -- The "Peptide Drug Conjugates Market Size, Share & Trends Analysis Report By Product (Lutetium, Melflufen, ANG1005, BT1718, CBX-12, Other Pipeline), By...
Global Radioligand Therapy Markets, 2020-2021 & 2022-2031: Expanding Radiopharmaceutical Coverage & Radioligand Therapy Demand Inclined by Rising Prevalence of Cancer
11 mai 2022 04h03 HE
|
Research and Markets
Dublin, May 11, 2022 (GLOBE NEWSWIRE) -- The "Radioligand Therapy Market - A Global and Regional Analysis: Focus on Indication, Product, Biomarker, and Region - Analysis and Forecast, 2021-2031"...
Cancer Treatment Centers of America Expands Neuroendocrine Tumor Clinical Program with Innovative Therapy for Rare Disease
23 avr. 2019 09h00 HE
|
Cancer Treatment Centers of America, Chicago
Chicago, Ill., April 23, 2019 (GLOBE NEWSWIRE) -- Physicians at Cancer Treatment Centers of America® (CTCA) Chicago have a new option in the fight against rare neuroendocrine tumors (NETs) with the...